Humanigen, Inc.

Johnson Fistel, Globally Recognized Law Firm, Encourages Shareholders to Submit Their Losses Below

SAN DIEGO, July 19, 2022 (GLOBE NEWSWIRE) — Shareholder rights law firm Johnson Fistel, LLP ( is investigating whether Humanigen, Inc. (“Humanigen” or “the Company”) (NASDAQ: HGEN), any of its executive officers, or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focus on investors’ losses and whether they may be recovered under the federal securities laws.

What if I purchased Humanigen common stock? If you purchased Humanigen common stock and suffered losses on your investment, join our investigation now:

Or for more information, contact Jim Baker at or (619) 814-4471

There is no cost or obligation to you.

What is Johnson Fistel investigating? On July 13, 2022, Humanigen disclosed that its trial of lenzilumab did not attain statistical significance on the primary endpoint of the proportion of subjects with baseline CRP<150 mg/L and aged below 85 years, alive and without needing mechanical ventilation through day 29.  

What if I have relevant nonpublic information? Individuals with nonpublic information regarding the company should consider whether to assist our investigation or take advantage of the SEC Whistleblower program. Under the SEC program, whistleblowers who provide original information may, under certain circumstances, receive rewards totaling up to thirty percent of any successful recovery made by the SEC. For more information, contact Jim Baker at (619) 814-4471 or

About Johnson Fistel, LLP. Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in securities class action and derivative lawsuits. For more information about the firm and its attorneys, please visit Attorney advertising. Past results do not guarantee future outcomes.


Johnson Fistel, LLP
Jim Baker, Lead Securities Analyst
Investor Relations
Telephone: (619) 814-4471